(Q38059150)

27 August 2017

title

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines (English)

1 reference

multidrug-resistant tuberculosis

27 August 2017

0 references

multiple drug resistance

1 reference

1 reference

1 reference

10

1 reference

Pere-Joan Cardona i Iglesias

27 August 2017

12

1 reference

27 August 2017

Tjip S van der Werf

14

0 references

Stefan Kaufmann

object named as

Stefan H E Kaufmann

13

0 references

Satria A Prabowo

object named as

Satria A Prabowo

1

0 references

author name string

Matthias I Gröschel

2

1 reference

27 August 2017

Ed D L Schmidt

3

1 reference

27 August 2017

Alena Skrahina

4

1 reference

27 August 2017

Traian Mihaescu

5

1 reference

27 August 2017

Serap Hastürk

6

1 reference

27 August 2017

Rotislav Mitrofanov

7

1 reference

27 August 2017

Edita Pimkina

8

1 reference

27 August 2017

Ildikó Visontai

9

1 reference

27 August 2017

John L Stanford

11

1 reference

27 August 2017

publication date

10 November 2012

1 reference

Medical Microbiology and Immunology

27 August 2017

published in

1 reference

27 August 2017

volume

202

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

95-104

1 reference

https://scigraph.springernature.com/pub.10.1007/s00430-012-0278-6

27 August 2017

exact match

0 references

cites work

Tuberculosis, drug resistance, and the history of modern medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The emergence of drug-resistant tuberculosis in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Scaling up interventions to achieve global tuberculosis control: progress and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

MDR tuberculosis--critical steps for prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Undermining the endothelium by ablation of MAPK-MEF2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Confronting multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Tuberculosis: cost of illness in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Totally drug-resistant tuberculosis in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Treatment of tuberculosis and optimal dosing schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Risk factors for multidrug resistant tuberculosis in Europe: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mycobacterium tuberculosis: immune evasion, latency and reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Innate immune recognition of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The immunology of tuberculosis: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Human macrophage host defense against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Inside or outside the phagosome? The controversy of the intracellular localization of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mycobacterium tuberculosis: here today, and here tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Lipid body-phagosome interaction in macrophages during infectious diseases: host defense or pathogen survival strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mycobacterial persistence requires the utilization of host cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Calmodulin regulates endosome fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Novel tuberculosis vaccination strategies based on understanding the immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Autophagy in the immune response to tuberculosis: clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

IL-4 in tuberculosis: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Bacterial growth and cell division: a mycobacterial perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

RUTI: a new chance to shorten the treatment of latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mycobacterium tuberculosis: success through dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Targeting persisters for tuberculosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Is adipose tissue a place for Mycobacterium tuberculosis persistence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Extrapulmonary locations of mycobacterium tuberculosis DNA during latent infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The secret trumps, impelling the pathogenicity of tubercle bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Nonreplicating persistence of mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The Mycobacterium tuberculosis ECF sigma factor sigmaE: role in global gene expression and survival in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The chemotherapy of tuberculosis: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Delamanid for multidrug-resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Tuberculosis vaccines: beyond bacille Calmette-Guerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

New vaccines for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The BCG World Atlas: a database of global BCG vaccination policies and practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Vaccines against tuberculosis: where are we and where do we need to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Update on research and development pipeline: tuberculosis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The origin of fibroblasts and mechanism of cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Immune protection against tuberculosis--when is immunotherapy preferable to vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Prospects for a new, safer and more effective TB vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Robert Koch and the pressures of scientific research: tuberculosis and tuberculin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The common mycobacterial antigens and their importance in the treatment of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Successful immunotherapy of canine flea allergy with injected Actinomycetales preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Adjunct immunotherapies for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Surgical treatment of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Treatment of tuberculosis: update 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Prevention of Experimental Myointimal Hyperplasia by Immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Nutritional status and vitamin D3 during antimicrobial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0278-6

Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB

21 January 2018

1 reference

12 December 2020

First tuberculosis cases in Italy resistant to all tested drugs.

1 reference

12 December 2020

Immunotherapy: a new strategy for tuberculosis control?

1 reference

12 December 2020

National survey of drug-resistant tuberculosis in China

1 reference

12 December 2020

Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type

1 reference

12 December 2020

Risk of development of tuberculosis in HIV-infected patients

1 reference

12 December 2020

A Further Communication on a Remedy for Tuberculosis.

1 reference

12 December 2020

IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses

1 reference

12 December 2020

Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model

1 reference

12 December 2020

IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner.

1 reference

12 December 2020

Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis

1 reference

12 December 2020

[Die Atiologie der Tuberculose. Facsimile of the original contribution by Robert Koch in "Berliner Klinische Wochenschrift" 10 April 1882]

1 reference

12 December 2020

Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales

1 reference

12 December 2020

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

1 reference

12 December 2020

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

The promise of immunotherapy for tuberculosis

1 reference

12 December 2020

Mycobacterium tuberculosis Invasion of Macrophages: Linking Bacterial Gene Expression to Environmental Cues

1 reference

12 December 2020

Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung

1 reference

12 December 2020

Revisiting the role of the granuloma in tuberculosis

1 reference

12 December 2020

Tuberculosis and granuloma formation in patients receiving anti-TNF therapy

1 reference

12 December 2020

Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein Tag

1 reference

12 December 2020

Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages

1 reference

12 December 2020

10.1007/S00430-012-0278-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1044105745

0 references

1 reference